FIG. 1A




FIG. 1B




FIG. 1C




FIG. 2A



Day 4
Day 9
Day 14
% BFP+ in viable cells
100
80
60
40
20
0
h62G7 -L6/EQ
14C11
20B9
32A10
42G9
C6
20E12
26B9
30D8
32G8

FIG. 2B



EGFRvIII-mFc
EGFR-mFc
% binding in viable cells
50
40
30
20
10
0
h62G7 -L6/EQ
14C11
20B9
32A10
42G9
C6
20E12
26B9
30D8
32G8

FIG. 2C



EGFRvIII-mFc
BFP +
% in viable cells
100
80
60
40
20
0
h62G7 -L6/EQ
14C11
20B9
32A10
42G9
C6
20E12
26B9
30D8
32G8

FIG. 3



CAR-T alone
NCI-H522
NCI-H522-EGFR vIII
U87-KO
U87-KO-EGFR wt
U87-KO-EGFR vIII
% CD107a+ in CD8+ cells
100
80
60
40
20
0
h62G7 -L6/EQ
14C11
20B9
32A10
42G9
C6
20E12
26B9
30D8
32G8

FIG. 4



150
100
50
0
IFNγ(ng/ml)
h62G7 -L6/EQ
14C11
20B9
32A10
42G9
C6
20E12
26B9
30D8
32G8
CAR-T alone
NCI-H522
NCI-H522-EGFR vIII
U87-KO
U87-KO-EGFR wt
U87-KO-EGFR vIII

FIG. 5



80
60
40
20
0
% specific cell lysis
h62G7 -L6/EQ
14C11
20B9
32A10
42G9
C6
20E12
26B9
30D8
32G8
NCI-H522-EGFR vIII
U87-KO-EGFR wt
U87-KO-EGFR vIII

FIG. 6



14C11 CAR T
32A10 CAR T
26B9 CAR T
Non-transduced T
Tumor Volume (mm3)
(Mean ± SEM)
1000
800
600
400
200
0
7
14
21
28
35
dose i.v.
Days Post Implantation

FIG. 7



% CAR+ in viable cells
100
80
60
40
20
0
Day 4
Day 9/10
Day 14/15
14C11-R2
32A10-R2
30D8-R2
26B9-R2
NTD

FIG. 8




% CAR+ in viable cells
80
60
40
20
0
Day 4
Day 14/15
14C11-R2
32A10-R2
30D8-R2
26B9-R2
NTD

FIG. 9


% specific cell lysis
80
60
40
20
0
U87-KO-EGFRvIII
NCI-H522-EGFRvIII
14C11-R2
32A10-R2
30D8-R2
26B9-R2